Hormone replacement therapy (HRT) was initiated almost half a century ago to treat menopausal symptoms. Initially, its use remained limited even among symptomatic women and the move toward postmenopausal hormone use f...Hormone replacement therapy (HRT) was initiated almost half a century ago to treat menopausal symptoms. Initially, its use remained limited even among symptomatic women and the move toward postmenopausal hormone use for disease prevention came later. Improved treatment schedules and delivery systems expanded the use of HRT worldwide. However, large trials of postmenopausal hormones with disease outcomes were even later in coming and today HRT has become a specialized, multidisciplinary area of research. As the population continues to grow older, there has been an increased focus on the effects of ageing. HRT may affect length and quality of life through disease prevention. It may have possible beneficial effects on cognition, on the incidence of hip fracture, myocardial infarction and stroke, and adverse effects on the incidence of breast cancer, endometrial cancer, and venous thromboembolism.Today’s attitudes about the hormonal treatments for the menopausal transition have moved from expansive optimism to contracting disappointment amidst safety concerns and equivocal results and faces greater skepticism and scrutiny. The health and well being of large numbers of women are at stake, and researchers, clinicians and the general public are watching and weighing the options.展开更多
Objective To observe the change of the cardiova scular effect of estrogen replaceme nt therapy in rat after treated with p rogesterone.Method Thirty female rates were randomly di vided into three groups:group A:ova ri...Objective To observe the change of the cardiova scular effect of estrogen replaceme nt therapy in rat after treated with p rogesterone.Method Thirty female rates were randomly di vided into three groups:group A:ova rietcomy;group B:ovariectomy with estrogen replacement therapy and group C:ovariectomy with estrogen and progesterone replacement therapy.The estrogen receptors(ER)in the artery of the rat were measured and the serum level of nitric oxide(NO),endothelin-1(ET-1),prostacyclin(PGF 1a )and thromboxane(TXB 2 )were detected 2months later.Results(1)There was no apparent difference in ER expression,serum NO and PGF 1a level between group C and group B;these index of group B and C were higher than those of group A;(2)there was no significant difference in blood viscosity,the congregate i ndex of red blood cell and platelet adhesiveness rate between group B and C;these index of group B and C were lower than those of group A.Conclusion Estrogen replacement therapy addin g progesterone makes no influence on arterial ER expression,hemorheolo gy index and regulation of estrogen t o cardiovascular cytokines generation.It suggested that estrogen combined with progesterone replacement t herapy could be a safe and effective method to prevent coronary heart dis ease.展开更多
Objective: To assess the effects of hormone replacement therapy (HRT) on plasma lipid levels and hormone levels in postmenopausal women. Methods: A total of 108 Chinese postmenopausal women with hyperlipodemia (mean a...Objective: To assess the effects of hormone replacement therapy (HRT) on plasma lipid levels and hormone levels in postmenopausal women. Methods: A total of 108 Chinese postmenopausal women with hyperlipodemia (mean age (65.3±0.7) years) were randomly divided into 3 groups (group Ⅰ , Ⅱ and Ⅲ). Patients in group Ⅰ received exclusive estrogen therapy (Premarin), those in group Ⅱ received combined therapy with estrogen and progestrone (Livial), and those in group Ⅲ were treated with placebo. At the end of 3 and 6 months of the therapy, the serum sex hormone and lipid levels were determined and compared with the baseline levels. Results: After 6 months’ therapy, in group Ⅰ, a statistically significant (P < 0.01) decrease or increase vs the baseline was observed in serum lipid levels: the tatal cholesteror (TC) dropped by 12.8%, triglyceride (TG) by 17%, low-density lipoprotein cholesterol (LDL-ch) by 29%, and high-density lipoprotein cholesterol (HDL-ch) was elevated by 14.6%. In group Ⅱ, TC levels was decreased by 8.7%, TG by 15.6%, LDL-ch by 33% and HDL-ch by 28.3%. The serum estradiol (E2) levels in both group Ⅰ and Ⅱ was increased significantly (P < 0.01). Conclusion: Estrogen replacement therapy (ERT) benefits the lipoprotein metabolism in postmenopausal women with hyperlipodemia but when progestational is added to the ERT, the beneficial effect of estrogen on blood lipids was reduced.展开更多
文摘Hormone replacement therapy (HRT) was initiated almost half a century ago to treat menopausal symptoms. Initially, its use remained limited even among symptomatic women and the move toward postmenopausal hormone use for disease prevention came later. Improved treatment schedules and delivery systems expanded the use of HRT worldwide. However, large trials of postmenopausal hormones with disease outcomes were even later in coming and today HRT has become a specialized, multidisciplinary area of research. As the population continues to grow older, there has been an increased focus on the effects of ageing. HRT may affect length and quality of life through disease prevention. It may have possible beneficial effects on cognition, on the incidence of hip fracture, myocardial infarction and stroke, and adverse effects on the incidence of breast cancer, endometrial cancer, and venous thromboembolism.Today’s attitudes about the hormonal treatments for the menopausal transition have moved from expansive optimism to contracting disappointment amidst safety concerns and equivocal results and faces greater skepticism and scrutiny. The health and well being of large numbers of women are at stake, and researchers, clinicians and the general public are watching and weighing the options.
文摘Objective To observe the change of the cardiova scular effect of estrogen replaceme nt therapy in rat after treated with p rogesterone.Method Thirty female rates were randomly di vided into three groups:group A:ova rietcomy;group B:ovariectomy with estrogen replacement therapy and group C:ovariectomy with estrogen and progesterone replacement therapy.The estrogen receptors(ER)in the artery of the rat were measured and the serum level of nitric oxide(NO),endothelin-1(ET-1),prostacyclin(PGF 1a )and thromboxane(TXB 2 )were detected 2months later.Results(1)There was no apparent difference in ER expression,serum NO and PGF 1a level between group C and group B;these index of group B and C were higher than those of group A;(2)there was no significant difference in blood viscosity,the congregate i ndex of red blood cell and platelet adhesiveness rate between group B and C;these index of group B and C were lower than those of group A.Conclusion Estrogen replacement therapy addin g progesterone makes no influence on arterial ER expression,hemorheolo gy index and regulation of estrogen t o cardiovascular cytokines generation.It suggested that estrogen combined with progesterone replacement t herapy could be a safe and effective method to prevent coronary heart dis ease.
基金Natural Science Foundation of China No. 39600169, Guangdong Natural Science Foundation No. 950845 and Key Item ofGuangdong Nat
文摘Objective: To assess the effects of hormone replacement therapy (HRT) on plasma lipid levels and hormone levels in postmenopausal women. Methods: A total of 108 Chinese postmenopausal women with hyperlipodemia (mean age (65.3±0.7) years) were randomly divided into 3 groups (group Ⅰ , Ⅱ and Ⅲ). Patients in group Ⅰ received exclusive estrogen therapy (Premarin), those in group Ⅱ received combined therapy with estrogen and progestrone (Livial), and those in group Ⅲ were treated with placebo. At the end of 3 and 6 months of the therapy, the serum sex hormone and lipid levels were determined and compared with the baseline levels. Results: After 6 months’ therapy, in group Ⅰ, a statistically significant (P < 0.01) decrease or increase vs the baseline was observed in serum lipid levels: the tatal cholesteror (TC) dropped by 12.8%, triglyceride (TG) by 17%, low-density lipoprotein cholesterol (LDL-ch) by 29%, and high-density lipoprotein cholesterol (HDL-ch) was elevated by 14.6%. In group Ⅱ, TC levels was decreased by 8.7%, TG by 15.6%, LDL-ch by 33% and HDL-ch by 28.3%. The serum estradiol (E2) levels in both group Ⅰ and Ⅱ was increased significantly (P < 0.01). Conclusion: Estrogen replacement therapy (ERT) benefits the lipoprotein metabolism in postmenopausal women with hyperlipodemia but when progestational is added to the ERT, the beneficial effect of estrogen on blood lipids was reduced.
